In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects

Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products

(2016) Gail D. Anderson et al.   CLINICAL PHARMACOKINETICS

Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice

(2016) Makiko Shimizu et al.   XENOBIOTICA

Assessment of potential drug–drug interactions and its associated factors in the hospitalized cardiac patients

(2016) Ghulam Murtaza et al.   SAUDI PHARMACEUTICAL JOURNAL

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

(2014) P. G. Richardson et al.   BLOOD

Pomalidomide: Evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects

(2014) Claudia Kasserra et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia

(2014) Naval Daver et al.   LEUKEMIA RESEARCH

Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma

(2013) Francesca Gay et al.   Expert Opinion on Drug Metabolism & Toxicology

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

(2013) Jesus San Miguel et al.   LANCET ONCOLOGY

Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration

(2012) Matthew Hoffmann et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Influence of cytochrome P450 oxidoreductase genetic polymorphisms on CYP1A2 activity and inducibility by smoking

(2012) Maria Dobrinas et al.   Pharmacogenetics and Genomics

Impact of Smoking, Smoking Cessation, and Genetic Polymorphisms on CYP1A2 Activity and Inducibility

(2011) M Dobrinas et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Consensus-Based Evaluation of Clinical Significance and Management of Anticancer Drug Interactions

(2011) Frank G.A. Jansman et al.   CLINICAL THERAPEUTICS

Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

(2008) Dan Zhu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

(2008) Ling Lu et al.   MICROVASCULAR RESEARCH